A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Checked against the public recordLast updated Jan 18, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- ImmunoGen, Inc.
- Interventions being studied
- Drug: IMGN901; Drug: Carboplatin and Etoposide
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients must be 18 years old * Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease * ECOG performance status of 0, 1, or 2 * No prior systemic chemotherapy for the treatment of SCLC Exclusion Criteria: \- Pregnant or lactating females
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Arizona Cancer Center @ UMC NorthTucson, Arizona
- UCLA Oncology CenterLos Angeles, California
- St. Joseph's HospitalOrange, California
- UCLA HematologyPasadena, California
- UCLA Oncology ClinicSanta Monica, California
- UCLA Santa Clarita Valley Cancer CenterValencia, California
- UCLA Oncology CenterWestlake Village, California
- Yale Medical CenterNew Haven, Connecticut
- Sibley Memorial HospitalWashington D.C., District of Columbia
- Holy Cross Hospital Bienes Comprehensive Cancer CenterFort Lauderdale, Florida
- University of FloridaGainesville, Florida
- Anne Arundel Medical CenterAnnapolis, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 18, 2018. Always confirm current availability with the study team.